Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2023; 29(17): 2642-2656
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2642
Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1
Hao Xu, Chang-Peng Chai, Xin Miao, Huan Tang, Jin-Jing Hu, Hui Zhang, Wen-Ce Zhou
Hao Xu, Chang-Peng Chai, Jin-Jing Hu, The Forth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
Xin Miao, State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of the Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730000, Gansu Province, China
Huan Tang, Wen-Ce Zhou, The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu Province, China
Hui Zhang, Wen-Ce Zhou, Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
Author contributions: Xu H designed and coordinated the study; Xu H, Chai CP, Miao X and Tang H performed the experiments, acquired and analyzed data; Xu H, Hu JJ and Zhang H interpreted the data; Xu H, Chai CP and Zhou WC wrote the manuscript; All authors have read and approve the final manuscript.
Supported by National Natural Science Foundation of China, No. 82260555; Gansu Provincial Science and Technology Plan, No. 1606RJZA139, No. 21JR11RA096, No. 21JR1RA099, and No. 21JR1RA113; Gansu Health Industry Project, No. GSWSKY2020-21; Traditional Chinese Medicine Scientific Research Project of Gansu Province, No. GZKP-2020-28; Talent Innovation and Entrepreneurship Project of Lanzhou, No. 2020-RC-46; Intra-Hospital Fund of the First Hospital of Lanzhou University, No. ldyyyn2019-97.
Institutional review board statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the First Hospital of Lanzhou University, No. LDYYLL-2022-487.
Institutional animal care and use committee statement: The animal study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the First Hospital of Lanzhou University, No. LDYYLL-2022-487.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao Xu, Doctor, MD, Associate Chief Physician, Surgeon, The Forth Department of General Surgery, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Lanzhou 730000, Gansu Province, China. amoyxu@126.com
Received: December 26, 2022
Peer-review started: December 26, 2022
First decision: February 8, 2023
Revised: February 17, 2023
Accepted: April 13, 2023
Article in press: April 13, 2023
Published online: May 7, 2023
Processing time: 132 Days and 2.8 Hours
ARTICLE HIGHLIGHTS
Research background

To date, only eight ampullary cancer cell lines have been reported, and a mixed-type ampullary carcinoma cell line has not yet been reported.

Research motivation

There is no ampullary cancer cell line of Chinese origin, and there is no report of mixed ampullary cancer cell line.

Research objectives

To establish a stable mixed-type ampullary carcinoma cell line originating from Chinese.

Research methods

Establish cell lines through primary culture and subculture, and identify their biological characteristics.

Research results

In this study, we successfully established and characterized of a mixed-type ampullary carcinoma cell line, DPC-X1, from the primary tumor of a patient with ampullary carcinoma.

Research conclusions

DPC-X1 can be used as an effective model for studying the pathogenesis of ampullary carcinoma and drug development.

Research perspectives

The establishment of ampullary carcinoma cell lines provides suitable experimental models for further study of ampullary carcinoma.